Search results
Results from the WOW.Com Content Network
The National Transportation Safety Board (NTSB) is set to provide an update Saturday on the investigation into the recent aircraft collision outside of Reagan Washington National Airport. More ...
The drug consists of a MTM1 transgene encapsulated in a viral vector from the adeno-associated virus class (AAV8) and is administered to affected children as an intravenous infusion. The treatment is being developed by Astellas Gene Therapies and is currently in a phase I/II clinical trial in the United States.
A 2021 U.S. Centers for Disease Control and Prevention poster on the COVID-19 viral vector vaccines. Viral vectors are modified viruses designed to deliver genetic material into cells. This process can be performed inside an organism or in cell culture. Viral vectors have widespread applications in basic research, agriculture, and medicine.
Because of AAV's specialized gene therapy advantages, researchers have created an altered version of AAV termed self-complementary adeno-associated virus (scAAV). Whereas AAV packages a single strand of DNA and must wait for its second strand to be synthesized, scAAV packages two shorter strands that are complementary to each other.
If the transgene is incorporated into somatic cells, the transgene will stay with the somatic cell line, and thus its host organism. [ 6 ] Gene delivery is a necessary step in gene therapy for the introduction or silencing of a gene to promote a therapeutic outcome in patients and also has applications in the genetic modification of crops.
Strasbourg, France, October 14, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic ...
Self-complementary adeno-associated virus (scAAV) is a viral vector engineered from the naturally occurring adeno-associated virus (AAV) to be used as a tool for gene therapy. [1] Use of recombinant AAV (rAAV) has been successful in clinical trials addressing a variety of diseases. [ 2 ]
For premium support please call: 800-290-4726 more ways to reach us